Valuation: Aquestive Therapeutics, Inc.

Market Cap 560M 492M 453M 424M 795M 52.85B 810M 5.44B 2.11B 26.05B 2.1B 2.06B 90.54B P/E 2026 *
-11x
P/E 2027 * -11.5x
Enterprise Value 475M 417M 385M 360M 674M 44.83B 687M 4.61B 1.79B 22.1B 1.78B 1.75B 76.8B EV / Sales 2026 *
9.41x
EV / Sales 2027 * 7.79x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-10.52%
1 week-5.20%
Current month+11.07%
1 month+8.37%
3 months+6.06%
6 months-25.21%
Current year-30.88%
1 week 4.16
Extreme 4.16
5.18
1 month 3.85
Extreme 3.85
5.18
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
06-23Fiscal year

Director

75,000 0.0598%
06-15Sell

Chief Executive Officer

-25,000 0.0199%
06-10Free

Director

50,500 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
-10.52%-5.20%+37.38%+143.99% 626M
+0.93%+2.65%+42.33%+145.77% 996B
+1.61%+7.22%+60.81%+47.98% 580B
+3.51%+12.31%+31.15%+78.88% 415B
+0.99%+5.11%+29.26%+21.27% 326B
+1.09%+6.90%+37.22%+23.11% 284B
+1.34%+6.74%+32.63%+38.93% 280B
+1.32%+12.69%-27.48%-42.00% 210B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 155B
Average -0.04%+4.08%+28.61%+57.31% 343.74B
Weighted average by Cap. +1.31%+4.81%+35.33%+70.20%

Financials

2026 *2027 *
Net sales 50.51M 44.37M 40.88M 38.22M 71.69M 4.77B 73M 490M 190M 2.35B 190M 186M 8.17B 71.92M 63.17M 58.2M 54.42M 102M 6.79B 104M 698M 270M 3.35B 270M 264M 11.63B
Net income -50.65M -44.49M -40.99M -38.33M -71.88M -4.78B -73.2M -492M -190M -2.36B -190M -186M -8.19B -47.99M -42.16M -38.84M -36.32M -68.12M -4.53B -69.37M -466M -181M -2.23B -180M -176M -7.76B
Net Debt -85M -74.66M -68.79M -64.32M -121M -8.02B -123M -825M -320M -3.95B -319M -312M -13.74B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
25/06/26 $4.465 -10.52% 5,170,865
24/06/26 $4.990 -0.80% 2,226,196
23/06/26 $5.030 +6.57% 2,988,647
22/06/26 $4.720 +0.21% 1,937,034
18/06/26 $4.710 +6.32% 3,138,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.465USD
Average target price
8.889USD
Spread / Average Target
+99.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock